Cidofovir Dihydrate
Modify Date: 2026-07-02 11:43:26
Cidofovir Dihydrate structure
|
Common Name | Cidofovir Dihydrate | ||
|---|---|---|---|---|
| CAS Number | 149394-66-1 | Molecular Weight | 315.22 | |
| Density | 1.8±0.1 g/cm3 | Boiling Point | 609.5±65.0 °C at 760 mmHg | |
| Molecular Formula | C8H18N3O8P | Melting Point | 260ºC (dec) | |
| MSDS | N/A | Flash Point | 322.4±34.3 °C | |
Use of Cidofovir DihydrateCidofovir dehydrate is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis, which suppresses virus replication by selective inhibition of viral DNA synthesis.Target: CMV DNA polymeraseCidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription. It is an acyclic nucleoside phosphonate, and is therefore independent of phosphorylation by viral enzymes, unlike acyclovir.Cidofovir was discovered at the Institute of Organic Chemistry and Biochemistry, Prague, by Antonín Hol?, and developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions. |
| Name | cidofovir dihydrate |
|---|---|
| Synonym | More Synonyms |
| Description | Cidofovir dehydrate is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis, which suppresses virus replication by selective inhibition of viral DNA synthesis.Target: CMV DNA polymeraseCidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription. It is an acyclic nucleoside phosphonate, and is therefore independent of phosphorylation by viral enzymes, unlike acyclovir.Cidofovir was discovered at the Institute of Organic Chemistry and Biochemistry, Prague, by Antonín Hol?, and developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.8±0.1 g/cm3 |
|---|---|
| Boiling Point | 609.5±65.0 °C at 760 mmHg |
| Melting Point | 260ºC (dec) |
| Molecular Formula | C8H18N3O8P |
| Molecular Weight | 315.22 |
| Flash Point | 322.4±34.3 °C |
| PSA | 157.71000 |
| LogP | -3.37 |
| Vapour Pressure | 0.0±4.0 mmHg at 25°C |
| Index of Refraction | 1.656 |
| InChIKey | FPKARFMSZDBYQF-ILKKLZGPSA-N |
| SMILES | Nc1ccn(CC(CO)OCP(=O)(O)O)c(=O)n1.O.O |
Total 489, Current Page 1 of 49
1
2
3
4
5
| Cidofovir hydrate (1:2) |
| Gs-0504 |
| Cidofovir dihydrate |
| ({[(2S)-1-(4-Amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid |
| Cidofovir |
| (S)-[[2-(4-Amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic Acid |
| Unii-jil713Q00n |
| (S)-HPMPC Hydrate |
| Cidovir Hydrate |
| Vistide Hydrate |
| (S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid |
| ({[(2S)-1-(4-Amino-2-oxo-1(2H)-pyrimidinyl)-3-hydroxy-2-propanyl]oxy}methyl)phosphonic acid |
| Vistide |
| Drg-0145 |
| Cidofovir hydrate |
| GS 0504 Hydrate |
| Cidofovir (dihydrate) |